Abstract CT036: Bioavailability of MK-3475A (pembrolizumab with berahyaluronidase alfa; “subcutaneous pembrolizumab”) in participants with advanced or metastatic solid tumors
The DOI matches its Crossref record.
Abstract
Background: Pembrolizumab is approved for treatment of multiple cancers as an intravenous (IV) infusion. Subcutaneous (SC) administration offers more convenience and flexibility in the clinic. We report results of the phase 1, open-label, 3475A-C18 study (NCT05017012) of MK-3475A (pembrolizumab with berahyaluronidase alfa [MK-5180], a variant of human hyaluronidase developed and manufactured by Alteogen Inc., for SC administration; “pembro SC”). Methods: Participants (pts) with unresectable advanced melanoma, metastatic non-small cell lung cancer (NSCLC), or advanced or metastatic renal cell carcinoma (RCC) were sequentially allocated to arms 1 (pembro SC 650 mg at 165 mg/mL) and 2 (pembro SC 650 mg at 130 mg/mL). In both arms, treatment cycles alternated between pembro SC Q6W and pembro 400 mg IV Q6W for 4 cycles, followed by ≤14 cycles of pembro IV Q6W; as appropriate, pts received platinum-doublet chemo (NSCLC) or axitinib (RCC). Blood samples for pharmacokinetic (PK) analyses were collected pre (cycles 1-4) and post (cycles 1-3) dose. Primary objectives: characterize the PK profile of pembro SC and estimate its bioavailability. Secondary objectives: evaluate anti-drug antibodies (ADA) against pembro SC; assess safety and tolerability of pembro SC. Tertiary objectives: evaluate systemic concentrations of and ADA against MK-5180. Results: 90 pts received pembro SC: 46 in arm 1, 44 in arm 2. 36% of pts had melanoma, 34% RCC, and 30% NSCLC. Median (range) PK results for pembro SC in cycle 1 were similar in arms 1 & 2: Cmax: 44.5 µg/mL (19.4-79.6) & 51.2 µg/mL (23.5-112); Ctrough: 15.1 µg/mL (3.76-36.1) & 16.0 µg/mL (0.595-44.4); AUC0-6wk: 1280 µg·day/mL (562-2382) & 1287 µg·day/mL (529-2648); Tmax: 6 days (3-10) & 5 days (2-10). Bioavailability and absorption rate were not meaningfully different between the two arms; mean estimated bioavailability of pembro SC was 61% (95% CI 58%-64%, CV 22%) and absorption rate was 0.301/day (95% CI 0.278-0.324, CV 43.7%). Pembro SC absorption phase was similar regardless of tumor type, injection site, or body weight. ADAs against pembro were detected in 2/83 (2%) evaluable pts. No pts had measurable MK-5180 concentrations after pembro SC dosing in the absence of positive predose samples. ADAs against MK-5180 were detected in 3/83 (4%) evaluable pts. On physical exam, 4 (9%) pts in arm 1 and 4 (9%) in arm 2 had injection site AEs in cycle 1; all events were nonserious and most were mild (grade 1). Conclusions: Pembro SC had an estimated bioavailability of 61%. Both formulation strengths (130 mg/mL and 165 mg/mL) had similar absorption PK and safety profiles. Systemic absorption of MK-5180 was negligible. Given the totality of data, pembro SC 790 mg Q6W at 165 mg/mL was selected for further clinical development, as it is expected to achieve exposures consistent with pembro IV 400 mg Q6W and allows for a smaller injection volume. Citation Format: Oscar Reig Torras, Graham Cohen, Byoung Chul Cho, Carlos Rojas, Cathryn Walton, Laura Medina, Richard Khanyile, Zsuzsanna Papai, Mallika Lala, Gina Song, Omobolaji Akala, Corlia Coetzee. Bioavailability of MK-3475A (pembrolizumab with berahyaluronidase alfa; “subcutaneous pembrolizumab”) in participants with advanced or metastatic solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT036.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Results of the C18 study informed the selection of the pembrolizumab dose and the pembrolizumab s.c.solution strength, 11,12 pembrolizumab s.c.790 mg at 165 mg/ml q6w, for further clinical development.”
Citations
Cites
Still being checked.
Cited by
Felip, E., Rojas, C. I., Schenker, M., Kowalski, D. M., Casarini, I. A., Csöszi, T., Şendur, M. A. N., Martins, J., Calles Blanco, A., Wang, C.-C., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.012 · Cited by 40
Self-citationSong, G. K., Erman, M., Martinengo, G. L., Kocsis, J., Kunta, G., Wang, M., Yoshioka, H., Silva, C. D. M., & Lala, M. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115711 · Cited by 5
Self-citationPavani, C., Gandhimathi, R., chandrudu, J., Gowri, R., Mubarakunnisa, Majeed, S., Muthukumarasamy, R., Nuli, M. V., & Gandla, P. K. (2026) · Green Analytical Chemistry · doi:10.1016/j.greeac.2026.100379
Metadata
- Authors
- Torras, O. R., Cohen, G., Cho, B. C., Rojas, C., Walton, C., Medina, L., Khanyile, R., Papai, Z., Lala, M., Song, G., Akala, O., & Coetzee, C.
- Affiliations
- 1Hospital Clínic de Barcelona, Barcelona, Spain;
- Life Groenkloof Hospital (ZA)
- Yonsei University (KR)
- 4Bradford Hill Investigación Clínica, Santiago, Chile;
- 5Bay Oncology, Gqeberha, South Africa;
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Steve Biko Hospital (ZA)
- 8Magyar Honvédség Egészségügyi Központ-Onkológiai Osztály, Budapest, Hungary;
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- 10Cape Town Oncology Trials, Cape Town, South Africa.
- Venue
- Cancer Research
- Published
- 2025-04-25
- Volume
- 85
- Issue
- 8_Supplement_2
- Pages
- CT036-CT036
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W4409822403
- Cited by
- 3
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- pembrolizumab, subcutaneous administration, bioavailability, pharmacokinetics, hyaluronidase, anti-drug antibodies, advanced melanoma, metastatic non-small cell lung cancer, renal cell carcinoma, immune checkpoint inhibitors, drug safety and tolerability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract CT036: Bioavailability of MK-3475A (pembrolizumab with berahyaluronidase alfa; “subcutaneous pembrolizumab”) in participants with advanced or metastatic solid tumors. https://app.cochat.ai/papers/10.1158/1538-7445.am2025-ct036
- The paper
- Torras, O. R., Cohen, G., Cho, B. C., Rojas, C., Walton, C., Medina, L., Khanyile, R., Papai, Z., Lala, M., Song, G., Akala, O., & Coetzee, C. (2025). Abstract CT036: Bioavailability of MK-3475A (pembrolizumab with berahyaluronidase alfa; “subcutaneous pembrolizumab”) in participants with advanced or metastatic solid tumors. Cancer Research. https://doi.org/10.1158/1538-7445.am2025-ct036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.